Analysts are on the Bearish side about Verastem Inc (NASDAQ:VSTM) this week.

October 13, 2017 - By Henry Gaston

 Analysts are on the Bearish side about Verastem Inc (NASDAQ:VSTM) this week.
Investors sentiment increased to 1.17 in 2017 Q2. Its up 0.07, from 1.1 in 2017Q1. It improved, as 5 investors sold Verastem Inc shares while 18 reduced holdings. 13 funds opened positions while 14 raised stakes. 8.68 million shares or 12.61% more from 7.71 million shares in 2017Q1 were reported.
Raymond James Fincl Services Advsrs Inc holds 11,970 shares. Fmr Ltd Liability Corporation owns 250,000 shares for 0% of their portfolio. Lpl Finance Ltd Liability Co owns 19,494 shares. 99,594 were accumulated by Art Advisors Limited Liability Corp. Jpmorgan Chase And owns 251 shares. Parsons Cap Mgmt Inc Ri owns 14,500 shares. Tfs Cap reported 29,495 shares or 0.03% of all its holdings. Susquehanna Grp Incorporated Ltd Liability Partnership reported 31,851 shares or 0% of all its holdings. Federated Invsts Pa owns 1,293 shares for 0% of their portfolio. Jacobs Levy Equity Management Inc owns 223,290 shares for 0.01% of their portfolio. Bridgeway Capital Incorporated reported 231,500 shares. Blackrock accumulated 394,247 shares. Morgan Stanley holds 0% or 9,815 shares. Hightower Advisors Limited Liability Company reported 0% of its portfolio in Verastem Inc (NASDAQ:VSTM). Wells Fargo And Company Mn reported 20,950 shares or 0% of all its holdings.

Since May 15, 2017, it had 1 buy, and 0 selling transactions for $73,500 activity.

Verastem Inc (NASDAQ:VSTM) Ratings Coverage

Among 10 analysts covering Verastem (NASDAQ:VSTM), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Verastem had 26 analyst reports since September 9, 2015 according to SRatingsIntel. The firm has “Buy” rating by Oppenheimer given on Wednesday, August 16. Oppenheimer maintained the stock with “Buy” rating in Tuesday, August 8 report. The stock of Verastem Inc (NASDAQ:VSTM) has “Buy” rating given on Wednesday, July 12 by Oppenheimer. The stock of Verastem Inc (NASDAQ:VSTM) earned “Hold” rating by Jefferies on Tuesday, September 29. Jefferies maintained Verastem Inc (NASDAQ:VSTM) on Monday, June 26 with “Hold” rating. The company was initiated on Wednesday, September 9 by Raymond James. The rating was maintained by Oppenheimer with “Buy” on Tuesday, July 25. H.C. Wainwright maintained Verastem Inc (NASDAQ:VSTM) rating on Thursday, September 17. H.C. Wainwright has “Buy” rating and $17 target. The rating was maintained by Oppenheimer with “Buy” on Monday, June 26. The firm earned “Neutral” rating on Tuesday, September 29 by UBS. Below is a list of Verastem Inc (NASDAQ:VSTM) latest ratings and price target changes.

25/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $17.0 Maintain
06/09/2017 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Overweight Upgrade
16/08/2017 Broker: Oppenheimer Rating: Buy Maintain
10/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.5000
08/08/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain
25/07/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain
12/07/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain
26/06/2017 Broker: Jefferies Rating: Hold New Target: $1.5000 Maintain
26/06/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain
16/06/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0000 Maintain

The stock decreased 3.97% or $0.18 on October 13, reaching $4.35. About 717,648 shares traded. Verastem Inc (NASDAQ:VSTM) has risen 71.53% since October 13, 2016 and is uptrending. It has outperformed by 54.83% the S&P500.

Verastem, Inc. is a biopharmaceutical company. The company has market cap of $160.92 million. The Firm is focused on discovering and developing drugs to improve outcomes for patients with cancer. It currently has negative earnings. The Firm operates in the segment of developing drugs for the treatment of cancer.

Another recent and important Verastem Inc (NASDAQ:VSTM) news was published by Businesswire.com which published an article titled: “Verastem Appoints NgocDiep Le, MD, PhD as Chief Medical Officer” on October 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.